Recruiting

Testing combination treatments for kidney cancer that returned after immunotherapy

Plain-English translation of NCT07049926 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing whether combining two experimental medications— and —can help treat kidney cancer that has returned or progressed after a patient received anti-PD-(L)1 immunotherapy. The study will first carefully monitor safety in a small group, then move to a larger phase to see how well the medication works. Researchers want to find better options for people whose cancer didn't respond to or came back after their previous immunotherapy treatment.

Some patients with advanced kidney cancer do not benefit from or eventually develop resistance to anti-PD-(L)1 immunotherapy, and their cancer returns or continues to grow. This trial exists to offer a new treatment option for these patients and to understand whether combining these two medications might be more effective than current alternatives.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or metastatic kidney cancer with a clear cell component that is unresectable (cannot be surgically removed)
your cancer came back during or within 24 months after finishing anti-PD-(L)1 adjuvant therapy (immunotherapy given after surgery to prevent recurrence)
you have not received any other systemic (whole-body) cancer treatments for advanced kidney cancer besides the anti-PD-(L)1 therapy
you are able to swallow oral medication daily
you have adequate organ function and well-controlled blood pressure, with or without blood pressure medications
you are willing to provide a tumor tissue sample for testing

You likely don't qualify if…

you have significant bleeding history, including coughing up blood, vomiting blood, or other serious bleeding episodes
you have had major heart disease, blood clots in your legs, or serious lung conditions like pulmonary fibrosis within the past year
you have had major surgery or serious wounds or bone fractures within 8 weeks before starting the study
you are currently taking strong medications that interfere with how your body processes these experimental drugs, and those medications cannot be stopped
you have moderate to severe liver disease or certain digestive system conditions that affect how your body absorbs medication

What participation looks like

Participants will take one or two of the experimental medications by mouth daily, either the combination of both drugs or alone, depending on which group they are assigned to. You will have regular visits for blood tests, scans, and check-ups to monitor how the treatment is working and watch for any side effects. Treatment will continue until your cancer progresses, you experience unmanageable side effects, or you and your doctor decide to stop.

AI-generated summary from trial data · Jul 6, 2026 · Not medical advice

Testing combination treatments for kidney cancer that returned after immunotherapy

What is this trial?

Do you qualify?

What participation looks like

Trial locations